@FierceMedDev: For device companies, clearance for expanded use of key products = more revenue. Story | Follow @FierceMedDev
@MarkHFierce: Singapore's Biosensors International could find itself with a new owner--a Chinese equity firm. Key to a rebound? More | Follow @MarkHFierce
@MichaelGFierce: New gold nanoshells could offer better delivery of cancer drugs using near-infrared light. Release | Follow @MichaelGFierce
@EmilyWFierce: Word on the street is that Apple is developing iWatch technology to detect heart attacks. Article | Follow @EmilyWFierce
> Apple's ($AAPL) rumored health-related device under development would reportedly detect when someone is about to have a heart attack. Story
> Baxter International's ($BAX) board of directors declared a quarterly dividend of 49 cents per Baxter common share. Item
> Covidien ($COV) said it is rolling out a new hydrophilic guidewire for catheter placement and other procedures to treat vascular diseases. Item
> Florida's VeriTeQ gained more CE markings for its new breast implants with enhanced safety technology. Item
> China expects to launch an expedited registration process for cutting-edge medical devices beginning on March 1. Blog
Biotech News
@FierceBiotech: Bayer moves forward in the Factor VIII hemophilia race, but Biogen is still in the lead, analyst says. More | Follow @FierceBiotech
@JohnCFierce: Looks like Actavis wants to buy Forest for $25B - not sure I really get the synergy. Story | Follow @JohnCFierce
@DamianFierce: After snow put the FDA on hold for much of last week, Chelsea Therapeutics expects Northera decision today. Release | Follow @DamianFierce
@EmilyMFierce: Role of adaptor protein could point the way for new diabetes, cancer treatments. More from FierceBiotechResearch. | Follow @EmilyMFierce
> Novartis beefs up its cancer immunotherapy pipeline with a biotech buyout. Story
> Servier stages an entry into high-stakes CAR-T showdown with Novartis. News
> Novimmune banks $66M for immunotherapies as IPO rumors surface. Article
> Akebia swings for a $75M IPO to get its anemia drug into Phase III. Brief
Pharma News
@FiercePharma: Germany may publicize its drug discounts, putting fear into Big Pharma's heart. Story | Follow @FiercePharma
@TracyStaton: Call them the KOLs of biopharma: Our report on the industry's most influential people. Report | Follow @TracyStaton
@EricPFierce: FDA Commish Hamburg hopeful about cooperation from Indian regulators but some were less enthused. News | Follow @EricPFierce
@CarlyHFierce: Best-read special report over Presidents' Day weekend: Top 10 generics makers by 2012 revenue. More | Follow @CarlyHFierce
> Actavis inks $25B deal for Forest in bid to build its brand stable. Piece
> Indian regulator says his agency will not expect domestic drugmakers to hit FDA standards. Item
CRO News
> Quintiles notches its first-ever $1B quarter as sales boom. Earnings
> Parexel's rebranding makes a perceptible shift in its eClinical biz. Story
> Charles River's turnaround pays off with a strong 2013. Story
> Theorem takes a dive into analytics with latest deal. News
> After a 'pivotal' year, AMRI expects another leap in 2014. Article
> Chiltern inks a deal with Karolinska Development. Item
Biotech IT News
> Illumina takes a leaf out of the tech playbook with its genomics startup accelerator. Story
> Twitter explains how Boehringer is winning on social media. Article
> MIT proposes using robotic arms to enable smaller, cheaper stroke trials. Story
> Data science consortium outlines a vision for the future of genomic Big Data. News
> CamNtech gets an FDA nod as wearable devices advance into clinical trials. Article
> China cracks down on 'false' bird flu rumors on social media. Brief
Biotech Research News
> Role of adaptor protein could point the way for new diabetes, cancer treatments. Story
> Stem cell switch in neural cells could help treat neurological disorders. Article
> GlaxoSmithKline joins a $115M antibiotics development initiative. News
> MedImmune, UCSF strike translational research deal. News
> BioLineRx shows effectiveness of leukemia drug in preclinical study. Article
> Compound protects mice from Parkinson's-like motor loss. Item
Pharma Manufacturing News
> Mylan recalls injectable drugs after pieces of label found in some vials. News
> FDA's Hamburg comes back from India with high hopes about quality standards. Article
> Shire gets FDA nod for a second U.S. plant to make Vpriv. Story
> Ben Venue Labs may be closed but it is still recalling products. News
> Hikma's remediation costs have been offset by doxycycline sales. Story
> Amgen responds to FDA warning letter over drug/device combos. Brief